



CHEPLAPHARM WINS AGAIN – FOR THE SECOND TIME IN A ROW CHEPLAPHARM GOT AWARDED AS ONE OF THE BEST MANAGED COMPANIES IN GERMANY

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted 'Axia Best Managed Companies Award' for the second time in a row. Thus, CHEPLAPHARM repeatedly demonstrates its innovational strength, its strategic vision and sustainable leadership culture.

“We are very proud to be honoured again”, states Sebastian F. Braun, CHEPLAPHARM’s CEO, “because it shows that we tied in with the achievements of the previous years and delivered an outstanding performance. CHEPLAPHARM has a fabulous team, for which I am much obliged for. Thus, we are well-equipped for the next big steps ahead.”

The Axia Best Managed Companies program is a contest carried out by Deloitte, Credit Suisse and the Federation of German Industries (BDI) such as the German magazine ‘WirtschaftsWoche’. Therefore, the award is a hallmark of excellence for prosperous mid-sized businesses. One of the reward’s unique characteristic is its internationality: Deloitte originated the Best Managed Companies Award in Canada in the 1990’s. It was Deloitte’s vision to establish a national and global network of outstandingly managed mid-sized businesses. CHEPLAPHARM now joins the list of prestigious companies like Rossmann and Develey and further emphasizes the importance of Mecklenburg-Western Pomerania as an excellent business location.



“As one of the laureates, CHEPLAPHARM convinces again with its premier corporate management – through high innovative strength, a long-ranged and forward-looking strategy and strong governance structures. CHEPLAPHARM therefore is not only a benchmark for saliently led mid-sized businesses, but stands allegorical for the future of the business location Germany”, Lutz Meyer, partner and leader of Deloitte’s mid-sized businesses program, points out.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years with projected annual sales of 650 million euros in 2020.

Please refer to www.cheplapharm.com for additional information.

Further information about Deloitte can be found at www2.deloitte.com/global/en.html and about ‘WirtschaftsWoche’ via www.wiwo.de/.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)